The challenges of translation
Cancer immunotherapy is a highly active area in translational medicine where the challenges and rewards of developing new drugs “from bench to bedside” become particularly visible. Here, we comment on both, the scientific and non‐scientific hurdles of this translational process using the example of...
Main Authors: | Helmut R Salih, Gundram Jung |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2019-12-01
|
Series: | EMBO Molecular Medicine |
Online Access: | https://doi.org/10.15252/emmm.201910874 |
Similar Items
-
An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer
by: Martina S. Lutz, et al.
Published: (2024-01-01) -
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
by: Jonas S. Heitmann, et al.
Published: (2021-02-01) -
1353 An Fc-optimized B7-H3-targeting antibody for treatment of ovarian cancer
by: Ilona Hagelstein, et al.
Published: (2023-11-01) -
Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
by: Latifa Zekri, et al.
Published: (2023-03-01) -
B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
by: Ilona Hagelstein, et al.
Published: (2022-10-01)